These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19954617)

  • 1. [Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients].
    Hu N; Zhu HL; Liu HW; Zeng CX; Meng WT; Liu T
    Zhonghua Xue Ye Xue Za Zhi; 2009 Sep; 30(9):596-600. PubMed ID: 19954617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of hOCT1 in patients with chronic myelogeneous leukemia treated by imatinib mesylate].
    Zheng CX; Zhu HL; Liu HW; Hu N; Meng WT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):893-6. PubMed ID: 19950608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience].
    Sacha T; Czekalska S; Foryciarz K; Zawada M; Florek I; Cwynar D; Wator G; Balwierz W; Skotnicki AB
    Przegl Lek; 2011; 68(4):191-5. PubMed ID: 21853672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
    Chen WW; Meng FY; Zhong JS; Yin CX; Wang ZX
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1405-8. PubMed ID: 22883199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
    Giannoudis A; Wang L; Jorgensen AL; Xinarianos G; Davies A; Pushpakom S; Liloglou T; Zhang JE; Austin G; Holyoake TL; Foroni L; Kottaridis PD; Müller MC; Pirmohamed M; Clark RE
    Blood; 2013 Jan; 121(4):628-37. PubMed ID: 23223357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
    Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
    Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
    Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
    Nardinelli L; Sanabani SS; Didone A; Ferreira Pde B; Serpa M; Novaes MM; Marchiani M; Ruiz AL; Lima IS; Chamone Dde A; Bendit I
    Acta Haematol; 2012; 127(4):228-34. PubMed ID: 22508387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
    Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
    Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.